Zoledronate is administered in the following manner:

- Treatment or prevention of osteoporosis in males or postmenopausal females 

- 5 mg IV once yearly

- Treatment or prevention of glucocorticoid-induced osteoporosis

- 5 mg IV once yearly

- Paget disease of bone 

- 5 mg IV once, retreatment can be considered in the setting of disease relapse/recurrence

- Hypercalcemia of malignancy 

- 3 to 4 mg IV once

- Multiple myeloma 

- 4 mg IV every 3 to 4 weeks

- Solid tumor bone metastasis

- 4 mg IV every 3 to 4 weeks

- Prevention of bone loss related to aromatase inhibitor therapy 

- 5 mg IV once every two years

- Prevention of bone loss related to androgen deprivation therapy 

- 5 mg IV once every two years

- Breast cancer adjuvant therapy 

- 4 mg IV once every 6 months for three years or 4 mg IV once every 3 months for two years

Dose adjustments may be necessary for patients with renal dysfunction and are as follows:

- Treatment or prevention of osteoporosis in males or postmenopausal females, treatment or prevention of glucocorticoid-induced osteoporosis, and Paget disease of bone

- Avoid use in the following situations:

- Patients with acute kidney injury 
- Patients with a creatinine clearance (CrCl) less than or equal to 35 mL/minute

- Hypercalcemia of malignancy

- Avoid use in patients with serum creatinine greater than 4.5 mg/dL

- Multiple myeloma and solid tumor bone metastasis

- Dose reduction is required in patients with CrCl less than or equal to 60 mL/min, but dosing intervals are not impacted

- CrCl 50 to 60 mL/min

- The dose should be adjusted to 3.5 mg


- CrCl 40 to 49 mL/min

- The dose should be adjusted to 3.3 mg


- CrCl 30 to 39 mL/min

- The dose should be adjusted to 3 mg